168 related articles for article (PubMed ID: 27987595)
21. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer : A single-centre retrospective study.
Sas-Korczyńska B; Łuczyńska E; Kamzol W; Sokołowski A
Strahlenther Onkol; 2017 Feb; 193(2):141-149. PubMed ID: 27785518
[TBL] [Abstract][Full Text] [Related]
22. Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.
Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP; Khuri FR; Curran WJ; Ramalingam SS; Behera M; Higgins KA
Clin Lung Cancer; 2019 Nov; 20(6):484-493.e6. PubMed ID: 31296433
[TBL] [Abstract][Full Text] [Related]
23. Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer.
Han D; Qin Q; Hao S; Huang W; Wei Y; Zhang Z; Wang Z; Li B
Radiat Oncol; 2014 Dec; 9():280. PubMed ID: 25498196
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
Giuliani ME; Atallah S; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
Clin Lung Cancer; 2011 Nov; 12(6):375-9. PubMed ID: 21729647
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
[TBL] [Abstract][Full Text] [Related]
27. Tumour volume changes assessed with high-quality KVCT in lung cancer patients undergoing concurrent chemoradiotherapy.
Lee YH; Kim YS; Lee HC; Lee SW; Kang YN; Kang JH; Hong SH; Kim YK; Kim SJ; Ahn MI; Han DH; Yoo IR; Park JG; Sung SW; Lee KY
Br J Radiol; 2015 Aug; 88(1052):20150156. PubMed ID: 26055505
[TBL] [Abstract][Full Text] [Related]
28. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
[TBL] [Abstract][Full Text] [Related]
29. No survival benefit with early incorporation of thoracic radiotherapy using daily fractionation in patients with limited-stage small cell lung cancer undergoing chemoradiotherapy in the modern era: A systematic review and meta-analysis.
Kim BH; Song C; Kim HJ
Radiother Oncol; 2023 Jul; 184():109696. PubMed ID: 37150449
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Lung Cancer; 2022 Apr; 166():49-57. PubMed ID: 35183991
[TBL] [Abstract][Full Text] [Related]
31. Timing of Thoracic Radiation Therapy With Chemotherapy in Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Current Practice Patterns.
Farrell MJ; Yahya JB; Degnin C; Chen Y; Holland JM; Henderson MA; Jaboin JJ; Harkenrider MM; Thomas CR; Mitin T
Clin Lung Cancer; 2018 Nov; 19(6):e815-e821. PubMed ID: 29857969
[TBL] [Abstract][Full Text] [Related]
32. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
[TBL] [Abstract][Full Text] [Related]
33. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA; Waqar SN; Mix MD
J Clin Oncol; 2022 Feb; 40(6):661-670. PubMed ID: 34985935
[TBL] [Abstract][Full Text] [Related]
34. The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer.
Sas-Korczynska B; Sokolowski A; Korzeniowski S
Lung Cancer; 2013 Jan; 79(1):14-9. PubMed ID: 23153659
[TBL] [Abstract][Full Text] [Related]
35. Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey.
Aynaci Ö; Canyilmaz E; Serdar L; Kandaz M; Bahat ZM; Yoney A
J Cancer Res Ther; 2016; 12(1):238-43. PubMed ID: 27072244
[TBL] [Abstract][Full Text] [Related]
36. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
37. Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Han TJ; Kim HJ; Wu HG; Heo DS; Kim YW; Lee SH
Jpn J Clin Oncol; 2012 Oct; 42(10):948-54. PubMed ID: 22811409
[TBL] [Abstract][Full Text] [Related]
38. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174
[TBL] [Abstract][Full Text] [Related]
39. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
[TBL] [Abstract][Full Text] [Related]
40. Can consolidative thoracic radiotherapy improve outcomes in extensive-disease small cell lung cancer after chemotherapy with complete/near-complete responders?
Kirakli EK; Yilmaz H; Akcay C; Komurcuoglu B; Yilmaz U
J Cancer Res Ther; 2020; 16(4):752-756. PubMed ID: 32930114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
